LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genetic Test Predicts Therapeutic Response in Pediatric Kidney Disease

By LabMedica International staff writers
Posted on 05 Aug 2014
Image: Histopathology of a child’s kidney showing one glomerulus (arrow) with matrix expansion and uniform thickening of the basement membrane. The tubules show mild atrophy and the interstitium contains patchy moderate infiltrates. The appearance is consistent with membranous nephropathy (Photo courtesy of Dr. S. K. Pradhan).
Image: Histopathology of a child’s kidney showing one glomerulus (arrow) with matrix expansion and uniform thickening of the basement membrane. The tubules show mild atrophy and the interstitium contains patchy moderate infiltrates. The appearance is consistent with membranous nephropathy (Photo courtesy of Dr. S. K. Pradhan).
Genetic mutations in the kidney’s filtration barrier are frequently linked with a lack of response to immunosuppressive treatments among children with sporadic nephrotic syndrome.

A genetic screening test may help predict which patients with one of the most common childhood kidney diseases will respond to standard therapies and using such a test could help guide clinicians as they counsel and treat patients.

Scientists at the University of Florence (Italy) designed an innovative diagnostic approach that allows for a fast analysis of all genes involved in the disease. The use of this method allowed the team to analyze 46 different genes at the same time in 69 children with the disease, and they found that genetic mutations in the kidney's filtration barrier were frequently linked with a lack of response to immunosuppressive treatments in patients.

DNA was extracted from peripheral blood using a QIAamp DNA Mini Kit (Qiagen; Hilden, Germany) , and the DNA libraries were constructed using Roche NimbleGen (Madison, WI, USA) sample preparation protocol (Rapid Library Preparation Method Manual). A Roche NimbleGen sequence capture array in a solution-based method was used to capture all coding exons and flanking regions of 46 genes. The array included 19 known genes responsible for nephrotic syndrome to potentially identify putative new genes, the other 27 candidate genes associated with proteinuria in animal models and expressed in the glomerular filtration barrier were included.

The innovative strategy allowed the teams to establish the existence of potentially pathogenic variants in 32.3% of 31 patients with sporadic steroid-resistance, whereas using the same technical approach, none of 38 additional patients who exhibited a similar clinical phenotype but were steroid-sensitive had genetic mutations in the analyzed genes. The authors concluded that the results of their study suggest that this type of genetic analysis may improve the approach to children with sporadic nephrotic syndrome by promoting better genetic counseling and management of the treatment.

Paola Romagnani, MD, PhD, the senior author of the study said, “This type of genetic analysis can improve the clinical approach to children with nephrotic syndrome by promoting better genetic counseling for the risk of recurrence of the disease in the family, and a better management of treatment and clinical follow up.” The study was published on July 24, 2014, in the Journal of the American Society of Nephrology.

Related Links:

University of Florence
Qiagen
Roche NimbleGen



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more